

Proton pump inhibitor-refractory gastroesophageal reflux solutions

Clinical and Experimental Gastroenterology

Volume 11, 119-134

DOI: [10.2147/ceg.s121056](https://doi.org/10.2147/ceg.s121056)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 864-872.	3.7	60
2	Validity and reliability of the reflux symptom score. <i>Laryngoscope</i> , 2020, 130, E98-E107.	2.0	97
3	A comparison of the efficacy and safety of complementary and alternative therapies for gastroesophageal reflux disease. <i>Medicine (United States)</i> , 2020, 99, e21318.	1.0	1
4	Weak acids induce PGE2 production in human oesophageal cells: novel mechanisms underlying GERD symptoms. <i>Scientific Reports</i> , 2020, 10, 20775.	3.3	2
5	Evaluation of serum levels of Interleukin-4 in Egyptian patients with refractory gastroesophageal reflux disease. <i>Alexandria Journal of Medicine</i> , 2020, 56, 196-202.	0.6	0
6	The first case of tegoprazan-induced urticaria. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1187-1189.	1.5	0
7	Use of proton pump inhibitors and risk of rosacea: A nationwide population-based study. <i>Journal of Dermatology</i> , 2020, 47, 1126-1130.	1.2	5
8	The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. <i>Esophagus</i> , 2021, 18, 144-151.	1.9	10
9	Efficacy and patient satisfaction of single-session transoral incisionless fundoplication and laparoscopic hernia repair. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 921-927.	2.4	11
10	The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 219-227.	1.8	12
11	Mucus barrier correction as a target in complex treatment of gastroesophageal reflux disease. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2021, 12, 22-26.	0.1	0
12	Differential Bile Acid Detection in Refractory GERD Patient Saliva Using a Simple and Sensitive Liquid Chromatography Tandem Mass Spectrometry Approach. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 218-223.	2.2	4
13	Endoscopic cardiac constriction with band ligation in the treatment of refractory gastroesophageal reflux disease: a preliminary feasibility study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 4035-4041.	2.4	7
14	Endoscopic Management of Gastroesophageal Reflux Disease. <i>Digestive Disease Interventions</i> , 0, 05, .	0.2	0
15	Correction of eating behavior in patients with erosive reflux esophagitis. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 71-84.	0.2	2
16	Gastro-esophageal reflux disease (GERD) after peroral endoscopic myotomy (POEM). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 3308-3316.	2.4	10
17	Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful <i>Helicobacter pylori</i> eradication therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-6.	1.5	1
18	Refractory Gastroesophageal Reflux Disease. <i>Physician Assistant Clinics</i> , 2021, 6, 613-623.	0.1	2

#	ARTICLE	IF	CITATIONS
19	The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 4.	0.9	2
21	Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1648-1657.	3.7	17
23	A PROSPECTIVE STUDY INVOLVING COMPARISON OF ACOTIAMIDE WITH RABEPRAZOLE VS. DOUBLE DOSE RABEPRAZOLE IN PATIENTS HAVING OVERLAPPING SYMPTOMS OF PROTON PUMP INHIBITOR REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPEPSIA. <i>International Journal of Research -GRANTHAALAYAH</i> , 2020, 8, 1-11.	0.1	0
24	Refractory Gastroesophageal Reflux Disease: A Management Update. <i>Frontiers in Medicine</i> , 2021, 8, 765061.	2.6	34
25	Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. <i>Iranian Journal of Public Health</i> , 2020, 49, 2264-2274.	0.5	1
26	Reflux Aspiration Associated with Oesophageal Dysmotility but Not Delayed Liquid Gastric Emptying. <i>Digestive Diseases</i> , 2021, 39, 429-434.	1.9	1
27	Complete Fundus Mobilization Reduces Dysphagia After Nissen Procedure. <i>Surgical Innovation</i> , 2021, 28, 272-283.	0.9	1
28	A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial. <i>Acta Biomedica</i> , 2020, 91, 70-78.	0.3	0
29	Buccal Buspirone as add-on Therapy to Omeprazole Versus Omeprazole in Treatment of Gastroesophageal Reflux Diseases (GERD). <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 113-120.	0.5	0
30	Treatment of Refractory Gastroesophageal Reflux Disease. <i>Gastroenterology and Hepatology</i> , 2020, 16, 196-205.	0.1	3
31	Beyond the Eckardt Score: Patient-Reported Outcomes Measures in Esophageal Disorders. <i>Current Gastroenterology Reports</i> , 2021, 23, 29.	2.5	5
32	Clinical profile and characteristics of eosinophilic esophagitis patients presenting with refractory gastroesophageal reflux disease in Makassar, Indonesia. <i>Pan African Medical Journal</i> , 2022, 41, 93.	0.8	1
33	The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD). <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 217-233.	3.0	1
34	Efficacy of Endoscopic Radiofrequency Ablation for Treatment of Reflux Hypersensitivity: A Study Based on Rome IV Criteria. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-8.	1.5	3
35	Chinese Medicine Formula Siwu-Yin Inhibits Esophageal Precancerous Lesions by Improving Intestinal Flora and Macrophage Polarization. <i>Frontiers in Pharmacology</i> , 2022, 13, 812386.	3.5	3
36	Combined Curcumin and Lansoprazole-Loaded Bioactive Solid Self-Nanoemulsifying Drug Delivery Systems (Bio-SSNEDDS). <i>Pharmaceutics</i> , 2022, 14, 2.	4.5	12
37	Endoscopic Removal of an Eroded LINX [®] Device Using a Mechanical Biliary Lithotripter. <i>Foregut</i> , 2022, 2, 89-95.	0.5	1
38	Nutritional Management of Children With Neurological Impairment in China: Current Status and Future Directions. <i>JPGN Reports</i> , 2022, 3, e164.	0.4	1

#	ARTICLE	IF	CITATIONS
39	Prospects in non-invasive diagnosis of bronchial asthma-related gastroesophageal reflux disease: a single-stage open uncontrolled non-randomised observational study. <i>Kuban Scientific Medical Bulletin</i> , 2021, 28, 14-28.	0.4	1
42	Protective Mechanisms of Liquid Formulations for Gastro-Oesophageal Reflux Disease in a Human Reconstructed Oesophageal Epithelium Model. <i>Medical Devices: Evidence and Research</i> , 0, Volume 15, 143-152.	0.8	0
43	Macrophage phenotype after human refluxate exposure, esophageal dysmotility and their correlation with gastroesophageal reflux disease. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2022, 32, 24-33.	1.1	0
44	Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials. <i>Terapevticheskii Arkhiv</i> , 2023, 94, 1407-1412.	0.8	0
45	Implementation of <i>CYP2C19</i> genotyping to guide proton pump inhibitor use at an academic health center. <i>American Journal of Health-System Pharmacy</i> , 2023, 80, 994-1003.	1.0	2
46	Syntropy of bronchial asthma and gastroesophageal reflux disease: pathogenetic features and possibilities of minimally invasive diagnostics at the outpatient stage. <i>Āno-Rossijskij Āurnal Terapevtičeskoj Praktiki</i> , 2023, 4, 25-34.	0.3	0
47	Features of GERD therapy in obese patients: A review. <i>Consilium Medicum</i> , 2023, 25, 361-367.	0.3	0
48	Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment. <i>Polymers</i> , 2023, 15, 3485.	4.5	4
49	Esophagoprotective agent in the treatment of gastroesophageal reflux disease in children. <i>Meditinskiy Sovet</i> , 2023, , 120-127.	0.5	0
50	Multicentre prospective study to evaluate effectiveness and safety of gel-forming and hyaluronic-acid containing chewable tablets as add-on treatment in patients with gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor therapy. <i>BMC Gastroenterology</i> , 2023, 23, .	2.0	0
51	Review article: Diagnosis and management of laryngopharyngeal reflux. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 616-631.	3.7	1
52	Abordaje de la enfermedad por reflujo gastroesofágico refractaria. <i>Revista De Gastroenterología Del Peru: Organo Oficial De La Sociedad De Gastroenterología Del Peru</i> , 2024, 44, 41-51.	0.2	0
53	Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux. <i>Ecological Management and Restoration</i> , 0, , .	0.4	0